Aerie's Rhopressa Approved Early For Glaucoma, 2018 Launch Planned
The first of Aerie's two glaucoma candidates, Rhopressa, was approved in the US and a submission for combination product Roclatan is expected next year. Rhopressa may have muted uptake in 2018, however, since it won't launch until the second quarter and half of its market is covered by Medicare Part D.
You may also be interested in...
The approval of combo therapy Rocklatan gives Aerie two approved glaucoma products; Rhopressa quickly attained wide market access in the US and Aerie expects Rocklatan to fare the same.
The agency's Dec. 21 approval of Giapreza became novel drug No. 46 of 2017, topping the 2015 mark of 45.
US FDA's Dermatologic and Ophthalmologic Drugs Advisory Committee votes in favor of efficacy of proposed glaucoma treatment, but several say only in patients with baseline intraocular pressure less than 25 mmHg.